Aquage – SalonQuest – Conair
Salon Hair Care Products
SalonQuest d/b/a Aquage Acquired by Conair Corp.
Founded in 1998 Aquage develops salon grade hair-styling and finishing products. The company has two main brands including Aquage and SeaExtend that offer hampoo, conditioner, dry shampoo, detangler, oil foam, gel and other related hair care products. It sells exclusively to independent salon owners with customers worldwide and is based in Chagrin Falls. Ohio.
Conair will invest in Aquage to fully unleash its potential – developing new products, entering new product categories, and driving further international expansion.
The determined efforts of the Pharus Advisors team with their extensive knowledge and experience of the beauty industry helped ensure we found a great home for our Company with Conair Professional Product’s Division. Pharus not only helped position and market our company to a broad audience of potential suitors, they worked tirelessly throughout the negotiation and diligence process to help ensure a truly smooth transaction. We wanted to find a partner who would bring incredible synergies to our company and enable us to invest in our business, expand into new categories and grow our brands internationally. Thanks to Pharus, we found just that partner in Conair.
Dennis LubinCEO & Co-Founder
Other Transactions
Medimetriks Pharmaceuticals Inc., an independent branded dermatology company, has divested exclusive US rights to MM36 (difamilast ointment) to Acrotech Biopharma LLC in a transaction consisting of upfront and pre and post-approval milestone payments of up to $200 million.
New Jersey
Medimetriks Pharmaceuticals Inc. divested exclusive US rights to MM36 (difamilast ointment)
R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. In exchange, Huadong will make an equity investment in R2 Dermatology to fund R2’s next phase of product and market development.
San Ramon, CA
R2 Technologies is the world leader in CryoAesthetics™ medical devices. Our Glacial® platform for precision contact cooling of the skin has been shown to reduce inflammation and also brighten dark spots.
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in Asia
High Point, NC
Tv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.
